Annolyse
BriefingsCompaniesInsightsPrinciplesCompareChatWatchlist

Explore

  • Briefings
  • Companies
  • Insights
  • Compare

Resources

  • Search
  • Methodology

© 2026 Annolyse.

ChartsAnalysisChatData
  1. Charts
  2. Analysis
  3. Chat
  4. Data
  5. Sources
←Back to briefings
Heartland Group Holdings (HGH) / FY22

PBT up 15.5% but NPAT growth held to 9.3% by higher tax rate

Net operating income grew 11.7% and PBT expansion outpaced it, while the effective tax rate rose to 30.6% from 26.6%, narrowing the NPAT result.

Financials / Banking and finance

HGH revenue trajectory

Revenue context before the current result.

↗
Loading chart...
HY26 was $172.3m, versus $322.9m in FY25.

HGH Operating profit margin

Operating profit margin across covered periods.

↗
Loading chart...
HY26 was 45.2%, versus 36.8% in HY25.

HGH operating cash flow

Operating cash flow across covered periods.

↗
Loading chart...
HY26 was $299.5m, versus $673.2m in FY25.

HGH working-capital movement

Operating working-capital absorption or release by reporting period.

↗
Loading chart...
FY24 was -$0.2m, versus $0.4m in FY23.
Release date
23 August 2022
Published
22 April 2026
Ask about this result
Sections⌄
  1. Charts
  2. Analysis
  3. Chat
  4. Data
  5. Sources

Key metrics

Numbers worth scanning first

FY22 vs FY21

Revenue

$280.6m

+11.7% ↑ vs $251.2m

Net profit after tax

$95.1m

+9.3% ↑ vs $87m

Net cash inflow from operating activities

−$262.3m

+22.7% ↑ vs −$339.5m

Full-year dividend per share

11.0c

flat vs 11.0c

Profit before tax

$137m

+15.5% ↑ vs $118.6m

Cash and cash equivalents

$310.8m

+70.4% ↑ vs $182.3m

Total assets

$7.1b

+24.9% ↑ vs $5.7b

What changed

Profit before tax rose 15.5% to $137.0m on net operating income growth of 11.7% to $280.6m, signalling positive operating leverage at the underlying-earnings line

Net profit after tax grew only 9.3% to $95.1m because the effective tax rate jumped to 30.6% from 26.6%, opening a 6.2 percentage-point gap between PBT and NPAT growth.

Return on equity edged higher to 11.8% from 11.4%. The declared final dividend was 5.5 cents per share, lower than the 7.0 cents prior final, while the full-year dividend per share was unchanged at 11.0 cents. The company-disclosed payout ratio against NPAT was 68.0%.

What matters

Tax, not trading, explains the NPAT gap

StockCo Australia acquisition adds balance-sheet context, with NZ$158m acquisition price, but borrowings and gearing are the direct leverage evidence.

The cleaner read of underlying earnings is PBT growth of 15.5%, which outpaced net operating income growth of 11.7%. The roughly 4 percentage-point rise in the effective tax rate is not explained in the supplied excerpts; until management clarifies the driver, it should be treated as the binding constraint on reported NPAT rather than a sign of weaker underlying trading.

Payout ratio against NPAT stepped up materially. With the full-year dividend unchanged at 11.0 cents and NPAT growing single digits, the payout ratio against NPAT rose to 68.2% from 46.7% in the prior comparable. This compresses retained earnings as a funding source for loan-book growth and increases the importance of deposits and external capital.

Segment mix remains concentrated. Motor Finance contributed 27.8% of segment results at $73.1m, while Australian and New Zealand reverse mortgages together contributed 27.3% at $71.7m. The concentration is relevant context for credit-quality and funding sensitivity, which the supplied excerpts do not address.

Expectations

No forward financial targets are supplied and the release excerpts do not provide a guidance range

The HY22 result delivered NPAT of $47.5m, exactly 50.0% of the full-year outcome, on net operating income of $130.8m representing 46.6% of the annual total. The shape implies marginally second-half-weighted revenue with broadly even profit phasing — a useful baseline for the next interim but not a substitute for management guidance, which the supplied material does not include.

Quality of result

The underlying business performed better than the NPAT line suggests

PBT grew faster than net operating income, ROE expanded modestly, and the negative operating cash flow typical of a finance issuer — where loan-book growth flows through operating activities — narrowed by $77.2m to $262.3m versus the prior comparable. Operating cash flow at this kind of issuer should not be read with the cash-conversion lens used for an operating company. Capex of $9.8m, at 3.5% of revenue, is modest and consistent with the prior comparable despite a 28.9% step-up in dollars.

The quality caveat sits in two places. First, until the move in the effective tax rate to 30.6% is explained, it is unclear whether that level is the new baseline or contains discrete items. Second, the supplied data does not disclose net interest margin, arrears, impairment expense, or capital adequacy — the more decision-relevant measures for a finance company — so a full earnings-quality read is not possible from this filing.

Unresolved

Open questions

Why did the effective tax rate rise from 26.6% to 30.6%, and is 30.6% the appropriate run-rate assumption for FY23?
What was the net interest margin trajectory through FY22, and how did arrears, impairment expense, and provision coverage move across the major lending segments?
How does management intend to fund continued loan-book growth given the payout ratio against NPAT has stepped up to 68.2%?
What is the group's capital adequacy position at year-end and how much regulatory headroom does it imply?
How sensitive are the Motor Finance and reverse mortgage books to rising interest rates and any cyclical credit deterioration?

This briefing cannot assess net interest margin direction, credit quality, capital adequacy headroom, or the durability of the year-on-year tax-rate change, because those disclosures are not present in the supplied data.

Chat

Ask about HGH FY22

Ask follow-up questions about Heartland Group Holdings's FY22 result.

Informational only. No buy, sell, hold, price-target, or personal financial advice.

Ask about HGH FY22

Informational only. No buy, sell, hold, price-target, or personal financial advice.

Sign in to chat

Sign in to ask questions about Heartland Group Holdings's FY22 result.

Why did the effective tax rate rise from 26.6% to 30.6%, and is 30.6% the appropriate run-rate assumption for FY23?Why does "Tax, not trading, explains the NPAT gap" matter?How strong was the cash and earnings quality in FY22?What should I watch next for HGH after FY22?

Checking account...

Data appendix

Show segment detail

Open to load segment breakdown.

Show analytical metrics

Open to load analytical metrics.

Show key metrics table

Open to load key metrics.

Sources

Current period

Results Announcement Template

FY22 / results announcement↗

Heartland FY22 Results and Offer Announcement

FY22 / results release↗

Heartland Group Holdings Financial Statements

FY22 / financial report↗

Investor Presentation

FY22 / results presentation↗

Prior comparable period

Heartland Group Holdings Financial Statements

FY21 / financial report↗

Heartland NZX Results Announcement Template

FY21 / results announcement↗

Heartland NZX Results Announcement Template

FY21 / results release↗

Interim context

Heartland - 1H2022 Investor presentation

HY22 / results presentation↗

Heartland - 1H2022 Results Release

HY22 / results release↗

Heartland - HGH Financial statements

HY22 / financial report↗

Heartland - NZX Results Announcement (template form)

HY22 / results announcement↗

Release context

Heartland Annual Meeting to be held online only

HY22 / commentary↗

Related insights

Cross-company views selected from the metrics in this briefing.

Earnings quality and statutory distortions

PBT and NPAT growth diverged by 6.2pp, with a distortion flag in the result.

→

Dividend coverage and payout pressure

Company-disclosed payout ratio is 68.0% on a NPAT basis, with NPAT payout at 68.2%.

→

Revenue growth context

Revenue growth was 11.7% for this reporting period.

→

ROE and capital efficiency

ROE was 11.8%, +0.4pp versus the prior comparable period.

→
This briefing is based on available company filings and standard Annolyse calculations. It is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.

Get notified when HGH publishes next

Get the next Heartland Group Holdings briefing and related NZX reporting-season updates by email.